BiotechTube

Trofinetide

Phase 2/3Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rett Syndrome

Conditions

Rett Syndrome

Trial Timeline

Sep 22, 2021 → May 31, 2023

NCT ID
NCT04988867

About Trofinetide

Trofinetide is a phase 2/3 stage product being developed by Acadia Pharmaceuticals for Rett Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT04988867. Target conditions include Rett Syndrome.

What happened to similar drugs?

3 of 9 similar drugs in Rett Syndrome were approved

Approved (3) Terminated (3) Active (3)
✅Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
✅Esomeprazole + LansoprazoleAstraZenecaApproved
✅Esomeprazole MagnesiumAstraZenecaApproved
❌GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
❌GWP42003-PJazz PharmaceuticalsPhase 3
❌trofinetideAcadia PharmaceuticalsPhase 3
🔄TrofinetideAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
15
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT04988867Phase 2/3Terminated
NCT04776746Phase 3Terminated
NCT04279314Phase 3Completed
NCT04181723Phase 3Completed

Competing Products

20 competing products in Rett Syndrome

See all competitors
ProductCompanyStageHype Score
Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
43
Esomeprazole + LansoprazoleAstraZenecaApproved
43
Esomeprazole MagnesiumAstraZenecaApproved
43
AZD5213 and placeboAstraZenecaPhase 2
35
fingolimod (FTY720)NovartisPhase 1/2
32
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
27
AripiprazoleBristol Myers SquibbPre-clinical
18
NBI-98854Neurocrine BiosciencesPhase 2
24
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
24
ValbenazineNeurocrine BiosciencesPhase 2
32
NBI-98854Neurocrine BiosciencesPhase 1
26
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
32
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
32
ValbenazineNeurocrine BiosciencesPhase 2
32
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
32
Abobotulinum toxin AIpsenPre-clinical
19
GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
29
GWP42003-PJazz PharmaceuticalsPhase 3
29
trofinetideAcadia PharmaceuticalsPhase 3
29
TrofinetideAcadia PharmaceuticalsPhase 3
37